Charlotte's Web
The high-CBD hemp cultivar that reshaped public perception of cannabis as medicine in the United States.
Charlotte's Web is genuinely historically important — it's the strain that put pediatric CBD on the front page and helped move U.S. hemp policy. But it's not a miracle plant, and a lot of what gets sold under the name today is unrelated CBD product riding a famous brand. The original cultivar is essentially industrial hemp by THC content. If you want the recreational high a typical dispensary flower delivers, this isn't it — that nickname 'Hippie's Disappointment' exists for a reason.
Overview
Charlotte's Web is a high-CBD, low-THC cannabis cultivar developed in Colorado by the Stanley brothers in the early 2010s. It was named for Charlotte Figi, a child with Dravet syndrome whose family reported dramatic reductions in seizure frequency after using an oil made from the plant — a story popularized by CNN's 2013 documentary Weed with Dr. Sanjay Gupta [1][2].
Chemically, Charlotte's Web is closer to industrial hemp than to a typical recreational cannabis strain. Independent reporting and the company's own descriptions place it at roughly 12–17% CBD and at or below 0.3% THC [2][3]. It does not produce a meaningful intoxicating effect at normal doses, which is why early growers reportedly called it 'Hippie's Disappointment' [2].
Its cultural importance is hard to overstate: Charlotte's Web was a central exhibit in the political case that led to expanded state-level CBD access laws, the FDA's later approval of Epidiolex (a purified CBD drug) for certain epilepsies [4], and ultimately the 2018 U.S. Farm Bill's legalization of hemp [5].
Chemistry
Charlotte's Web is a chemotype III plant — CBD-dominant with negligible THC Strong evidence. Published certificates of analysis and reporting consistently show CBD in the low- to mid-teens by dry weight and THC under the U.S. federal hemp limit of 0.3% [2][3].
Minor cannabinoids reported in the cultivar include CBG, CBC, and trace THCV, though concentrations vary by phenotype and grow conditions. There is no peer-reviewed terpene profile of the original Charlotte's Web cultivar in the public literature that we can verify; vendor-reported profiles commonly list myrcene, pinene, and caryophyllene as prominent, but these should be treated as batch-level claims rather than a definitive cultivar fingerprint Weak / limited.
It's worth separating the plant from the product. 'Charlotte's Web' is now also a consumer brand selling hemp extracts; the cannabinoid content of those bottled products is formulated and standardized, not a direct readout of the flower's chemistry.
Reported effects
There are no controlled clinical trials of Charlotte's Web the cultivar in humans. What exists is (a) the well-known case series and anecdotal reports surrounding Charlotte Figi and other pediatric epilepsy patients, and (b) the much larger clinical evidence base for purified CBD (Epidiolex), which is a different product made by a different company [4].
Users and caregivers commonly report:
- No noticeable intoxication or euphoria Strong evidence
- Subjective calming, reduced anxiety, and improved sleep Anecdote
- Reduced seizure frequency in some pediatric epilepsy cases Weak / limited — the strongest signal here comes from open-label observational studies of artisanal high-CBD extracts, which are prone to selection and reporting bias [6]
The rigorous evidence that CBD reduces seizures in Dravet syndrome and Lennox–Gastaut syndrome comes from randomized trials of pharmaceutical-grade CBD, not Charlotte's Web specifically [4] Strong evidence. Extrapolating those results to any given hemp extract is reasonable in broad strokes but not in dose-specific detail.
Lineage
Charlotte's Web's lineage is disputed and incompletely documented Disputed. The Stanley brothers have described it as originating from a high-CBD industrial hemp cross they called 'Hippie's Disappointment,' selectively bred and stabilized for CBD content [2]. Beyond that, no verified, peer-reviewed pedigree exists in the public record.
Genetic studies of commercial cannabis have repeatedly shown that strain names are unreliable indicators of underlying genetics [7]. Plants sold as 'Charlotte's Web' from different sources are not guaranteed to be genetically identical to the Stanley brothers' original line. Treat any detailed ancestry chart you see on seed-bank or strain-database websites as folklore unless it cites a verifiable breeder record.
Cultivation basics
Charlotte's Web is grown both outdoors at scale (as hemp) and indoors by smaller operators. General notes from growers and licensed hemp producers:
- Flowering time: roughly 9 weeks indoors; outdoors it finishes in early- to mid-October at temperate North American latitudes.
- Structure: medium-height, moderately branchy plants typical of high-CBD hemp.
- THC compliance risk: even a CBD-dominant chemotype III plant can drift above the 0.3% THC legal hemp limit if stressed or harvested late. Compliance testing close to harvest is standard practice for licensed hemp growers [5].
- Difficulty: moderate. Not especially finicky, but commercial growers prioritize even canopy and timely harvest to stay under THC limits.
Public, verified data on indoor yield specific to this cultivar is thin; figures on strain-finder sites are mostly user-submitted and should be treated as estimates, not specifications.
Marketing vs. reality
A few honest clarifications worth keeping straight:
- The plant and the brand are not the same thing. 'Charlotte's Web' is also a publicly traded hemp-products company (Charlotte's Web Holdings). Bottles on store shelves are formulated extracts, not a guarantee that you're consuming the genetics of the original cultivar.
- CBD ≠ Charlotte's Web. Many products marketed alongside the Charlotte's Web story use unrelated hemp biomass. CBD's clinical effects, where established, come from controlled-dose trials of purified CBD [4], not from any one cultivar's magic.
- It will not get you high. At ≤0.3% THC, this is functionally a hemp plant. People expecting recreational effects are routinely disappointed — hence the original nickname [2].
- The Charlotte Figi story is real, but it's one case. It catalyzed enormous policy change, and that's significant. It is not, by itself, clinical evidence that this specific cultivar treats epilepsy. The clinical evidence for CBD in epilepsy stands on its own from later randomized trials [4][6].
Charlotte's Web matters historically. Treat the rest of the marketing with the skepticism you'd apply to any other branded health product.
Sources
- Reported Young, S. (2013). 'Marijuana stops child's severe seizures.' CNN, August 7, 2013. ↗
- Reported Maa, E. & Figi, P. (2014). 'The case for medical marijuana in epilepsy.' Epilepsia, 55(6), 783–786.
- Reported Foley, R. (2014). 'A Tale of Two Strains: Charlotte's Web and the Politics of Medical Marijuana.' Vox / various outlets coverage of Stanley Brothers operations, 2014–2015.
- Peer-reviewed Devinsky, O. et al. (2017). 'Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.' New England Journal of Medicine, 376(21), 2011–2020.
- Government U.S. Congress (2018). Agriculture Improvement Act of 2018 ('2018 Farm Bill'), Public Law 115-334, Section 10113 (hemp definition and legalization). ↗
- Peer-reviewed Press, C. A., Knupp, K. G., & Chapman, K. E. (2015). 'Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy.' Epilepsy & Behavior, 45, 49–52.
- Peer-reviewed Sawler, J. et al. (2015). 'The Genetic Structure of Marijuana and Hemp.' PLoS ONE, 10(8), e0133292.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.